Premenstrual Dysphoric Disorder - 09/05/19

Doi : 10.1016/j.mcna.2019.02.007

Teresa Lanza di Scalea, MD, PhD ^a,^⁎ , Teri Pearlstein, MD ^b
^a Assistant Professor of Psychiatry and Women’s Health, Dell Medical School, University of Texas at Austin, Austin, TX, USA
^b Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Women’s Behavioral Medicine, Women’s Medicine Collaborative, Miriam Hospital, 146 West River Street, Providence, RI 02904, USA

^∗Corresponding author.

Resumen

Premenstrual dysphoric disorder (PMDD) comprises emotional and physical symptoms and functional impairment that lie on the severe end of the continuum of premenstrual symptoms. Women with PMDD have a differential response to normal hormonal fluctuations. This susceptibility may involve the serotonin system, altered sensitivity of the GABA_A receptor to the neurosteroid allopregnanalone, and altered brain circuitry involving emotional and cognitive functions. Serotonin reuptake inhibitors are considered the first-line treatment. Second-line treatments include oral contraceptives containing drospirenone, other ovulation suppression methods, calcium, chasteberry, and cognitive-behavioral therapy.

El texto completo de este artículo está disponible en PDF.

Keywords : Premenstrual syndrome, Premenstrual dysphoric disorder, Etiology, Antidepressant, Oral contraceptive, Treatment

Esquema

Other ovulation-suppression treatments

Other medications

Dietary supplements

Herbal and complementary treatments

Lifestyle modifications and psychosocial treatments

Summary

	This article originally appeared in the Psychiatric Clinics of North America, Volume 40, Issue 2, June 2017.
	Disclosures: Neither author has any commercial or financial conflicts of interest or any funding source for this article.